Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.
When patients with pacemakers die, what happens to the device? Typically, it ends up being discarded and forgotten—they were designed to be single-use devices, after all—but that does not have to be the case.
